Targeted drug regorafenib tested in rare thyroid cancer

NCT ID NCT02657551

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II study tests the targeted therapy regorafenib (Stivarga) in 8 people with metastatic medullary thyroid cancer that has progressed after prior treatment. The drug aims to block cancer growth by targeting specific proteins. Researchers are measuring how long participants live without the cancer getting worse, and tracking side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib (Stivarga)
What this could lead to: If successful, this could provide a new treatment option for people with advanced thyroid cancer who have not responded to prior therapies.
What could go wrong: This is a very small, early-phase trial with only 8 participants, so results may not apply broadly. Regorafenib can cause serious side effects like high blood pressure, liver problems, and bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MEDULLARY THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

medullary thyroid gland carcinoma thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CANCER

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Yale Cancer Center

New Haven, Connecticut, 06520-8028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.